Previous 10 | Next 10 |
home / stock / cerew / cerew news
Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission Data readouts from tavapadon Phase 3 TEMPO program expected beginning in the first half of 2023 ...
Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021 IND submitted for CVL-871 in dementia-related apathy Conference call and webcast scheduled for today at 8:00 AM EDT CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE)...
CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate...
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2020 financial results on Wedn...
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health...
Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator Company Expects to File U.S. IND Applications in 2021 for PDE4B and Kappa Opioid Receptor Agonist Preclinical Programs Live webcast today from 9:00 to 11:0...
Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cerevel Therap...
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an indep...
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a live webcast providing a current corporate overview, followed by ...
BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside c...
News, Short Squeeze, Breakout and More Instantly...
Cerevel Therapeutics Holdings Inc. Warrant Company Name:
CEREW Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in...
On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents...
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2...